Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by State Street Corp

State Street Corp lifted its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN) by 7.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,824,517 shares of the company’s stock after purchasing an additional 1,047,896 shares during the quarter. State Street Corp owned about 5.50% of Ocugen worth $15,701,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in OCGN. Xponance Inc. purchased a new stake in Ocugen in the second quarter valued at approximately $25,000. Victory Capital Management Inc. acquired a new position in shares of Ocugen during the second quarter worth about $51,000. Daiwa Securities Group Inc. acquired a new stake in shares of Ocugen in the second quarter valued at about $67,000. E Fund Management Co. Ltd. purchased a new stake in shares of Ocugen during the 2nd quarter valued at about $75,000. Finally, SG Americas Securities LLC acquired a new position in Ocugen during the 3rd quarter worth approximately $87,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on OCGN shares. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Ocugen in a report on Monday, November 18th. Maxim Group assumed coverage on shares of Ocugen in a research note on Tuesday, October 15th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research report on Monday, November 11th.

Ocugen Price Performance

Shares of NASDAQ:OCGN opened at $0.72 on Wednesday. Ocugen, Inc. has a 12 month low of $0.46 and a 12 month high of $2.11. The stock has a market cap of $209.23 million, a price-to-earnings ratio of -3.99 and a beta of 3.82. The stock’s 50 day moving average price is $0.92 and its 200 day moving average price is $1.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.58 and a quick ratio of 2.58.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.